Hutchmed (China) Limited (HCM) has released an update.
HUTCHMED (China) Limited has announced that China’s National Medical Products Administration is reviewing its supplemental New Drug Application for savolitinib, a treatment for certain types of advanced lung cancer. This could lead to an expanded indication for savolitinib, potentially benefiting more patients in China. The drug has shown promising results in clinical trials, with a median progression-free survival of 13.7 months for treatment-naïve patients and has been marketed in China under the brand name ORPATHYS®.
For further insights into HCM stock, check out TipRanks’ Stock Analysis page.
